Prime Medicine Inc (PRME) News

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

-- Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT;...

Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology...

Form 8-K - Current report

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety...

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

-- On-track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND or CTA...

Form 8-K - Current report

Prime Medicine Unveils Strategically Focused Pipeline

-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform...

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

Collaboration Combines Prime Medicine’s Precise, Multiplex Gene Editing Capabilities with Bristol Myers...

Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]